Health

Add as a preferred source on Google

Solti Outlines Digital Monitoring Trial for HER2-Positive Breast Cancer

TOP-REAL plans to enroll about 300 patients in Spain, France and Germany to track treatment toxicities, interruptions and quality-of-life measures.

Updated 2 min read
A patient enters an oncology hospital in Barcelona as clinicians use remote monitoring devices nearby. / EconoTimes.ai
A patient enters an oncology hospital in Barcelona as clinicians use remote monitoring devices nearby. / EconoTimes.ai

Solti has outlined TOP-REAL, a European study that will test whether remote patient data can help doctors spot treatment-related toxicities sooner in first-line therapy for locally advanced or metastatic HER2-positive breast cancer.

The study is sponsored by Solti, with Unicancer in France and Westdeutsche Studiengruppe (WSG) in Germany as collaborators. The European Union’s Clinical Trials Information System lists AstraZeneca as a source of monetary support.

TOP-REAL plans to enroll about 300 patients who have not previously received chemotherapy or HER2-targeted treatment for advanced or metastatic disease. The EU registry lists 62 sites, while Solti’s study page lists 23 participating centers.

Recruitment began in Spain on Feb. 18, 2026, Germany on July 24, 2026, and France on Oct. 2, 2026, according to the EU registry. The record lists the trial as ongoing and shows that no results have been submitted.

Solti said the monitoring approach will combine electronic patient-reported outcomes, pulse oximetry, smartwatch-based physiological readings and alerts exchanged between hospital visits. Researchers will examine adverse-event management, treatment interruptions or dose reductions, unplanned health-care use, adherence to the digital tools and quality-of-life measures.

The primary objectives are the time until a patient receives a first subsequent anticancer treatment and the time until a 10% decline in physical functioning on the EORTC QLQ-C30 questionnaire.

The trial addresses a safety concern amid evidence that the drug combination improves progression-free survival. In the phase III DESTINY-Breast09 trial, median progression-free survival was 40.7 months with trastuzumab deruxtecan and pertuzumab, compared with 26.9 months for a taxane, trastuzumab and pertuzumab; the hazard ratio for progression or death was 0.56.

Drug-related interstitial lung disease or pneumonitis occurred in 46 of 383 patients, or 12.1%, receiving the combination, with two fatal cases, according to an American Society of Clinical Oncology abstract. The U.S. Food and Drug Administration’s label for trastuzumab deruxtecan carries a boxed warning on the condition, including fatal cases, and directs clinicians to investigate new respiratory symptoms promptly.

“We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment,” Cristina Saura, TOP-REAL’s principal investigator, said in Solti’s announcement.

Related articles

View all